About Novo Nordisk A/S

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. This Denmark-based company's operations encompass the entire value chain from discovery, development, production, and marketing of pharmaceutical products. Its major projects are centered on advancing medications for diabetes, obesity, hemophilia, and growth disorders. Novo Nordisk's key objectives include driving change to defeat diabetes and other serious chronic conditions, ensuring sustainable financial performance, and leveraging quality as a competitive advantage. The company's aspiration is to have a remarkable impact on the lives of patients and healthcare professionals.

Snapshot

Public USOwnership

1923Year founded

53848Employees

Bagsværd, DenmarkHead office

Loading Map...

Global footprint

Operations

All Locations

Kingdom of Denmark

Products and/or services of Novo Nordisk A/S

GLP-1 agonists: This class of drugs, including Ozempic (semaglutide) and Wegovy, stimulates insulin production and has other beneficial effects like reducing weight and cardiovascular risk. They are considered a major breakthrough in diabetes treatment.
Basal insulins: These long-acting insulins, like Levemir and Tresiba, provide steady background insulin throughout the day to manage blood sugar levels. They are essential for many people with Type 1 and Type 2 diabetes.
Rapid-acting insulins: These short-acting insulins, like NovoLog and Novolin R, mimic the body's natural insulin response to meals and help control blood sugar after eating.
Recombinant clotting factors: These drugs, like NovoSeven and NovoEight, replace missing clotting factors in patients with hemophilia, allowing them to control bleeding episodes and improve their quality of life.
Somatropin: This growth hormone, sold under brands like Norditropin and Nutropin, is used to treat growth hormone deficiency in children and adults, resulting in improved height and other health benefits.
Diabetes management apps and programs: Novo Nordisk offers various digital tools like the mySugr app and the Six Seconds Challenge program to help people with diabetes track their blood sugar, take medications, and learn about managing their condition.

Novo Nordisk A/S executive team

Mr. Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board
Mr. Maziar Mike DoustdarPresident, CEO & Member of the Management Board
Mr. Henrik Ehlers WulffExecutive VP of CMC & Product Supply and Member of the Management Board
Mr. Ludovic HelfgottExecutive VP of Product & Portfolio Strategy and Member of Management Board
Dr. Martin Holst LangeEVP of R&D, Chief Scientific Officer and Member of the Management Board
Ms. Tania SabroeEVP of People, Organisation and Corporate Affairs & Member of Management Board
Mr. David S. MooreExecutive VP of US Operations & Member of Management Board
Ms. Thilde Hummel BogebjergExecutive VP of Quality, IT & Environmental Affairs and Member of Management Board
Mr. Emil Kongshoej LarsenEVP of International Operations & Member of Management Board
Jacob Martin Wiborg RodeHead of Investor Relations